01779.HK
LONGBIO-B
HKSE · Healthcare · Biotechnology · CN
HKD 128.00
+4.07%Aug 21, 2026, 09:52 UTC
Tianchen Biopharmaceutical announced its interim results for the six months ended June 2026, reporting a net loss of RMB 135 million, wider than the RMB 94.208 million loss in the same period last year, with a loss per share of RMB 2.18 and no dividend.
Source:Aug 21, 2026, 00:56 UTC
Tianchen Biopharmaceutical-B announced that its self-developed anti-IgE antibody LP-003 for seasonal allergic rhinitis has had its Biologics License Application accepted by China's National Medical Products Administration.
Source: